The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how high quality products have led to rapid success.
You have worked in pharma all of your life including for AstraZeneca, Ivax, Zentiva and LEO Pharma. Two years ago you decided to move from a rather sophisticated position into taking up responsibility to build up Cipla’s operations completely from scratch. What was the rationale behind this decision?
The Czech Republic was naturally among the first countries to establish operations in! Located at the geographic center of Europe, having a huge potential in the respiratory segment, transparent rules and regulations, and all products in the respiratory segment fully reimbursed by the system made it one of the best prospects.
